Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 16/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8171335 | 0.90 | ROCK1 (0.46) | ROCK1ROCK2 | |
| SCHEMBL8166917 | 0.88 | ROCK1 (0.44) | ROCK1ROCK2 | |
| SCHEMBL8166436 | 0.87 | ROCK1 (0.45) | ROCK1ROCK2 | |
| SCHEMBL8166227 | 0.87 | ROCK1 (0.44) | ROCK1ROCK2SMN1; SMN2 | |
| SCHEMBL8172938 | 0.85 | ROCK1 (0.40) | ROCK1ROCK2 | |
| SCHEMBL8173430 | 0.83 | ROCK1 (0.39) | ROCK1ROCK2 | |
| SCHEMBL8166429 | 0.80 | POLB (0.41) | ROCK1ROCK2METTL3 | |
| SCHEMBL8166309 | 0.76 | THRB (0.39) | ROCK1ROCK2 | |
| SCHEMBL8173845 | 0.76 | PTK2 (0.41) | ROCK1ROCK2SMN1; SMN2 | |
| SCHEMBL8179482 | 0.72 | PTK2 (0.40) | ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155728-B1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | claimed |
| EP-2155728-B1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| EP-2155728-B1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-8334309-B2 | Heterocyclic indazole derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20110190355-A1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-04 | — | — | US | disclosed |
| WO-2008138448-A2 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190355-A1 | HETEROCYCLIC INDAZOLE DERIVATIVES | SGK3, SGK2, SGK1 | ROCK1 576/4885ROCK2 842/4885SMN1; SMN2 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.